|
1
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and
Haber DA: Activating mutations in the epidermal growth factor
receptor underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Di Nicolantonio F, Martini M, Molinari F,
Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L,
Frattini M, Siena S and Bardelli A: Wild-type BRAF is required for
response to panitumumab or cetuximab in metastatic colorectal
cancer. J Clin Oncol. 26:5705–5712. 2008.
|
|
3
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M,
Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day
SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J,
Nelson B, Hou J, Lee RJ, Flaherty KT and McArthur GA; BRIM-3 Study
Group. Improved survival with vemurafenib in melanoma with BRAF
V600E mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carvajal RD, Antonescu CR, Wolchok JD,
Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ,
Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N,
Vemula S, Bouvier N, Bastian BC and Schwartz GK: KIT as a
therapeutic target in metastatic melanoma. JAMA. 305:2327–2334.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee LG, Connell CR and Bloch W: Allelic
discrimination by nick-translation PCR with fluorogenic probes.
Nucleic Acids Res. 21:3761–3766. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liew M, Pryor R, Palais R, Meadows C,
Erali M, Lyon E and Wittwer C: Genotyping of single-nucleotide
polymorphisms by high-resolution melting of small amplicons. Clin
Chem. 50:1156–1164. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M,
Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu
R and Patterson SD: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fornaro L, Lonardi S, Masi G, Loupakis F,
Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile
G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo
M, Zagonel V and Falcone A: FOLFOXIRI in combination with
panitumumab as first-line treatment in quadruple wild-type (KRAS,
NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II
trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol.
24:2062–2067. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reddi HV: Mutations in the EGFR pathway:
clinical utility and testing strategies. Clin Lab News. 39:14–16.
2013.
|
|
10
|
Schmid K, Oehl N, Wrba F, Pirker R, Pirker
C and Filipits M: EGFR/KRAS/BRAF mutations in primary lung
adenocarcinomas and corresponding locoregional lymph node
metastases. Clin Cancer Res. 15:4554–4560. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tuononen K, Mäki-Nevala S, Sarhadi VK,
Wirtanen A, Rönty M, Salmenkivi K, Andrews JM, Telaranta-Keerie AI,
Hannula S, Lagström S, Ellonen P, Knuuttila A and Knuutila S:
Comparison of targeted next-generation sequencing (NGS) and
real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on
formalin-fixed, paraffin-embedded tumor material of non-small cell
lung carcinoma-superiority of NGS. Genes Chromosomes Cancer.
52:503–511. 2013. View Article : Google Scholar
|
|
12
|
McCourt CM, McArt DG, Mills K, Catherwood
MA, Maxwell P, Waugh DJ, Hamilton P, O’Sullivan JM and Salto-Tellez
M: Validation of next generation sequencing technologies in
comparison to current diagnostic gold standards for BRAF, EGFR and
KRAS mutational analysis. PLoS One. 8:e696042013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Misale S, Yaeger R, Hobor S, Scala E,
Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,
Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C,
Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro
V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D and
Bardelli A: Emergence of KRAS mutations and acquired resistance to
anti-EGFR therapy in colorectal cancer. Nature. 486:532–536.
2012.PubMed/NCBI
|
|
14
|
Tejpar S, Celik I, Schlichting M,
Sartorius U, Bokemeyer C and Van Cutsem E: Association of KRAS G13D
tumor mutations with outcome in patients with metastatic colorectal
cancer treated with first-line chemotherapy with or without
cetuximab. J Clin Oncol. 30:3570–3577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Della Starza I, De Novi LA, Nunes V, Del
Giudice I, Ilari C, Marinelli M, Negulici AD, Vitale A, Chiaretti
S, Foà R and Guarini A: Whole-genome amplification for the
detection of molecular targets and minimal residual disease
monitoring in acute lymphoblastic leukaemia. Br J Haematol.
165:341–348. 2014.PubMed/NCBI
|
|
16
|
Hasmats J, Gréen H, Orear C, Validire P,
Huss M, Käller M and Lundeberg J: Assessment of whole genome
amplification for sequence capture and massively parallel
sequencing. PLoS One. 9:e847852014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vogelstein B, Sur S and Prives C: p53: the
most frequently altered gene in human cancers. Nat Educat.
3:62010.
|
|
18
|
Végran F, Rebucci M, Chevrier S, Cadouot
M, Boidot R and Lizard-Nacol S: Only missense mutations affecting
the DNA binding domain of p53 influence outcomes in patients with
breast carcinoma. PLoS One. 8:e551032013.PubMed/NCBI
|
|
19
|
Ma PC, Jagadeeswaran R, Jagadeesh S,
Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K,
Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG and
Salgia R: Functional expression and mutations of c-Met and its
therapeutic inhibition with SU11274 and small interfering RNA in
non-small cell lung cancer. Cancer Res. 65:1479–1488. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tanizaki J, Okamoto I, Okamoto K, Takezawa
K, Kuwata K, Yamaguchi H and Nakagawa K: MET tyrosine kinase
inhibitor crizotinib (PF-02341066) shows differential antitumor
effects in non-small cell lung cancer according to MET alterations.
J Thorac Oncol. 6:1624–1631. 2011. View Article : Google Scholar
|
|
21
|
Markowitz S, Wang J, Myeroff L, Parsons R,
Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein
B, et al: Inactivation of the type II TGF-beta receptor in colon
cancer cells with microsatellite instability. Science.
268:1336–1338. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Woodford-Richens KL, Rowan AJ, Gorman P,
Halford S, Bicknell DC, Wasan HS, Roylance RR, Bodmer WF and
Tomlinson IP: SMAD4 mutations in colorectal cancer probably occur
before chromosomal instability, but after divergence of the
microsatellite instability pathway. Proc Natl Acad Sci USA.
98:9719–9723. 2001. View Article : Google Scholar
|
|
23
|
Struewing JP: Genomic approaches to
identifying breast cancer susceptibility factors. Breast Dis.
19:3–9. 2004.PubMed/NCBI
|
|
24
|
Debiec-Rychter M, Cools J, Dumez H, Sciot
R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J,
Hagemeijer A, Van Oosterom A and Marynen P: Mechanisms of
resistance to imatinib mesylate in gastrointestinal stromal tumors
and activity of the PKC412 inhibitor against imatinib-resistant
mutants. Gastroenterology. 128:270–279. 2005. View Article : Google Scholar
|
|
25
|
Glubb DM, Cerri E, Giese A, Zhang W, Mirza
O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW,
Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K and Innocenti
F: Novel functional germline variants in the VEGF receptor 2 gene
and their effect on gene expression and microvessel density in lung
cancer. Clin Cancer Res. 17:5257–5267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Albuquerque C, Breukel C, van der Luijt R,
Fidalgo P, Lage P, Slors FJ, Leitão CN, Fodde R and Smits R: The
‘just-right’ signaling model: APC somatic mutations are selected
based on a specific level of activation of the beta-catenin
signaling cascade. Hum Mol Genet. 11:1549–1560. 2012.
|
|
27
|
Fratev FF and Jónsdóttir SO: An in silico
study of the molecular basis of B-RAF activation and conformational
stability. BMC Struct Biol. 9:472009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Klein O, Clements A, Menzies AM, O’Toole
S, Kefford RF and Long GV: BRAF inhibitor activity in V600R
metastatic melanoma. Eur J Cancer. 49:1073–1079. 2013. View Article : Google Scholar
|
|
29
|
Grabellus F, Worm K, Sheu SY, Siffert W,
Schmid KW and Bachmann HS: The prevalence of the c-kit exon 10
variant, M541L, in aggressive fibromatosis does not differ from the
general population. J Clin Pathol. 64:1021–1024. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Davis H, Lewis A, Behrens A and Tomlinson
I: Investigation of the atypical FBXW7 mutation spectrum in human
tumours by conditional expression of a heterozygous propellor tip
missense allele in the mouse intestines. Gut. 63:792–799. 2014.
View Article : Google Scholar
|
|
31
|
Imielinski M, Berger AH, Hammerman PS,
Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M,
Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P,
Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H,
Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C,
Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler
W, Kwiatkowski D, Johnson BE, Jänne PA, Miller VA, Pao W, Travis
WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G
and Meyerson M: Mapping the hallmarks of lung adenocarcinoma with
massively parallel sequencing. Cell. 150:1107–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Piccaluga PP, Bianchini M and Martinelli
G: Novel FLT3 point mutation in acute myeloid leukaemia. Lancet
Oncol. 4:6042003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ward PS, Cross JR, Lu C, Weigert O,
Abel-Wahab O, Levine RL, Weinstock DM, Sharp KA and Thompson CB:
Identification of additional IDH mutations associated with
oncometabolite R(−)-2-hydroxyglutarate production. Oncogene.
31:2491–2498. 2012.PubMed/NCBI
|
|
34
|
Jaiswal BS, Janakiraman V, Kljavin NM,
Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring
P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J,
Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ,
Backer JM and Seshagiri S: Somatic mutations in p85alpha promote
tumorigenesis through class IA PI3K activation. Cancer Cell.
16:463–474. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Miyaki M, Iijima T, Konishi M, Sakai K,
Ishii A, Yasuno M, Hishima T, Koike M, Shitara N, Iwama T,
Utsunomiya J, Kuroki T and Mori T: Higher frequency of Smad4 gene
mutation in human colorectal cancer with distant metastasis.
Oncogene. 18:3098–3103. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype: lessons from recent developments in the IARC TP53
database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar
|
